Male breast cancer

Breast Care

Volumn 3, Issue 3, 2008, Pages 183-189

  Rudlowski, Christian ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Breast cancer; Etiology; Male; Pathology; Therapy

Indexed keywords

AMPHETAMINE; ANASTROZOLE; ANDROGEN; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; BRCA1 PROTEIN; BRCA2 PROTEIN; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; ESTRONE; FOLLITROPIN; FULVESTRANT; GONADORELIN AGONIST; GOSERELIN; PROLACTIN; TAMOXIFEN; TAXANE DERIVATIVE; TESTOSTERONE; TRASTUZUMAB;

ADJUVANT THERAPY; ALGORITHM; ANDROGEN DEFICIENCY; BREAST BIOPSY; BREAST CANCER; BREAST CARCINOGENESIS; BREAST DISEASE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; CANCER RISK; CANCER STAGING; CANCER SUSCEPTIBILITY; CIGARETTE SMOKING; CLINICAL FEATURE; CLINICAL PRACTICE; CRYPTORCHISM; DIAGNOSTIC VALUE; DISEASE PREDISPOSITION; DRUG ABUSE; ECHOMAMMOGRAPHY; ENVIRONMENTAL EXPOSURE; ESTROGEN BLOOD LEVEL; ESTROGEN THERAPY; ETHNIC GROUP; EVIDENCE BASED MEDICINE; FAMILY HISTORY; FEMINIZATION; GENE MUTATION; GENETIC COUNSELING; GYNECOMASTIA; HEAD INJURY; HISTOPATHOLOGY; HUMAN; INCIDENCE; JEW; KLINEFELTER SYNDROME; LIVER CIRRHOSIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MALE; MALE BREAST; MAMMOGRAPHY; MASTECTOMY; METASTASIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; OCCUPATIONAL EXPOSURE; PRACTICE GUIDELINE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; PROLACTIN BLOOD LEVEL; PROSTATE CANCER; REVIEW; RISK FACTOR; SEX DIFFERENCE; TESTIS INJURY; TRANSSEXUALISM; WEIGHT GAIN;

EID: 46849102406     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000136825     Document Type: Review

References (56)

1. Sasco AJ, Lowenfels AB, Pasker-de Jong P: Review article: epidemiology of male breast cancer. A meta-analysis of published case-control studies and discussion of selected aetiological factors. Int J Cancer 1993;53:538-549.
2. Nahleh Z, Girnius S: Male breast cancer: a gender issue. Nat Clin Pract Oncol 2006;3:428-437.
3. Agrawal A, Ayantunde AA, Rampaul R, Robertson JF: Male breast cancer: a review of clinical management. Breast Cancer Res Treat 2007;103:11-21.
4. La Vecchia C, Levi F, Lucchini F: Descriptive epidemiology of male breast cancer in Europe. Int J Cancer 1992;51:62-66.
5. Hsing AW, McLaughlin JK, Cocco P, Co Chien HT, Fraumeni JF Jr: Risk factors for male breast cancer (United States). Cancer Causes Control 1998;9:269-275.
6. Scheike O, Svenstrup B, Frandsen VA: Male breast cancer. II. Metabolism of oestradiol-17 beta in men with breast cancer. J Steroid Biochem 1973;4:489-501.
7. Weiss JR, Moysich KB, Swede H: Epidemiology of male breast cancer. Cancer Epidemiol Biomarkers Prev 2005;14:20-26.
8. Fentiman IS, Fourquet A, Hortobagyi GN: Male breast cancer. Lancet 2006;367:595-604.
9. Wells S: Gynecomastia and male breast cancer. Radiol Technol 1994;65:331-333.
10. Basham VM, Lipscombe JM, Ward JM, Gayther SA, Ponder BA, Easton DF, Pharoah PD: BRCA1 and BRCA2 mutations in a population-based study of male breast cancer. Breast Cancer Res 2002;4:R2.
11. Rosenblatt KA, Thomas DB, McTiernan A, Austin MA, Stalsberg H, Stemhagen A, Thompson WD, Curnen MG, Satariano W, Austin DF: Breast cancer in men: aspects of familial aggregation. J Natl Cancer Inst 1991;83:849-854.
12. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998;62:676-689.
13. Gudmundsdottir K, Thorlacius S, Jonasson JG, Sigfusson BF, Tryggvadottir L, Eyfjord JE: CYP17 promoter polymorphism and breast cancer risk in males and females in relation to BRCA2 status. Br J Cancer 2003;88:933-936.
14. Ohayon T, Gal I, Baruch RG, Szabo C, Friedman E: CHEK2*1100delC and male breast cancer risk in Israel. Int J Cancer 2004;108:479-480.
15. Scheike O: Male breast cancer. 5. Clinical manifestations in 257 cases in Denmark. Br J Cancer 1973;28:552-561.
16. Heller KS, Rosen PP, Schottenfeld D, Ashikari R, Kinne DW: Male breast cancer: a clinicopathologic study of 97 cases. Ann Surg 1978;188:60-65.
17. Borgen PI, Wong GY, Vlamis V, Potter C, Hoffmann B, Kinne DW, Osborne MP, McKinnon WM: Current management of male breast cancer. A review of 104 cases. Ann Surg 1992;215:451-457.
18. Giordano SH: A review of the diagnosis and management of male breast cancer. Oncologist 2005;10:471-479.
19. Clark JL, Nguyen PL, Jaszcz WB, Jatoi A, Niehans GA: Prognostic variables in male breast cancer. Am Surg 2000;66:502-511.
20. Cutuli B, Dilhuydy JM, De Lafontan B, Berlie J, Lacroze M, Lesaunier F, Graic Y, Tortochaux J, Resbeut M, Lesimple T, Gamelin E, Campana F, Reme-Saumon M, Moncho-Bernier V, Cuilliere JC, Marchal C, De Gislain G, N'Guyen TD, Teissier E, Velten M: Ductal carcinoma in situ of the male breast. Analysis of 31 cases. Eur J Cancer 1997;33:35-38.
21. Ciatto S, Iossa A, Bonardi R, Pacini P: Male breast carcinoma: review of a multicenter series of 150 cases. Coordinating Center and Writing Committee of FONCAM (National Task Force for Breast Cancer), Italy. Tumori 1990;76:555-558.
22. Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi G: Breast carcinoma in men: a population-based study. Cancer 2004;101:51-57.
23. Rudlowski C, Friedrichs N, Faridi A, Fuzesi L, Moll R, Bastert G, Rath W, Buttner R: Her-2/neu gene amplification and protein expression in primary male breast cancer. Breast Cancer Res Treat 2004;84:215-223.
24. Kidwai N, Gong Y, Sun X, Deshpande CG, Yeldandi AV, Rao MS, Badve S: Expression of androgen receptor and prostate-specific antigen in male breast carcinoma. Breast Cancer Res 2004;6:R18-R23.
25. Appelbaum AH, Evans GF, Levy KR, Amirkhan RH, Schumpert TD: Mammographic appearances of male breast disease. Radiographics 1999;19:559-568.
26. Chen L, Chantra PK, Larsen LH, Barton P, Rohitopakarn M, Zhu EQ, Bassett LW: Imaging characteristics of malignant lesions of the male breast. Radiographics 2006;26:993-1006.
27. Newman J: Breast cancer in men and mammography of the male breast. Radiol Technol 1997;69:17-28.
28. Morakkabati-Spitz N, Schild HH, Leutner CC, von Falkenhausen M, Lutterbey G, Kuhl CK: Dynamic contrast-enhanced breast MR imaging in men: preliminary results. Radiology 2006;238:438-445.
29. Peate I: Caring for men with breast cancer: causes, symptoms and treatment. Br J Nurs 2001;10:975-981.
30. Hecht JR, Winchester DJ: Male breast cancer. Am J Clin Pathol 1994;102:S25-S30.
31. Cutuli B, Lacroze M, Dilhuydy JM, Velten M, De Lafontan B, Marchal C, Resbeut M, Graic Y, Campana F, Moncho-Bernier V: Male breast cancer: results of the treatments and prognostic factors in 397 cases. Eur J Cancer 1995;31A:1960-1964.
32. Guinee VF, Olsson H, Moller T, Shallenberger RC, van den Blink JW, Peter Z, Durand M, Dische S, Cleton FJ, Zewuster R: The prognosis of breast cancer in males. A report of 335 cases. Cancer 1993;71:154-161.
33. Willsher PC, Leach IH, Ellis IO, Bourke JB, Blamey RW, Robertson JF: A comparison outcome of male breast cancer with female breast cancer. Am J Surg 1997;173:185-188.
34. Scott-Conner CE, Jochimsen PR, Menck HR, Winchester DJ: An analysis of male and female breast cancer treatment and survival among demographically identical pairs of patients. Surgery 1999;126:775-780.
35. Gough DB, Donohue JH, Evans MM, Pernicone PJ, Wold LE, Naessens JM, O'Brien PC: A 50-year experience of male breast cancer: is outcome changing? Surg Oncol 1993;2:325-333.
36. Yildirim E, Berberoglu U: Male breast cancer: a 22-year experience. Eur J Surg Oncol 1998;24:548-552.
37. Albo D, Ames FC, Hunt KK, Ross MI, Singletary SE, Kuerer HM: Evaluation of lymph node status in male breast cancer patients: a role for sentinel lymph node biopsy. Breast Cancer Res Treat 2003;77:9-14.
38. Cimmino VM, Degnim AC, Sabel MS, Diehl KM, Newman LA, Chang AE: Efficacy of sentinel lymph node biopsy in male breast cancer. J Surg Oncol 2004;86:74-77.
39. Goyal A, Horgan K, Kissin M, Yiangou C, Sibbering M, Lansdown M, Newcombe RG, Mansel RE, Chetty U, Ell P, Fallowfield L, Kissin M: Sentinel lymph node biopsy in male breast cancer patients. Eur J Surg Oncol 2004;30:480-483.
40. Port ER, Fey JV, Cody HS, III, Borgen PI: Sentinel lymph node biopsy in patients with male breast carcinoma. Cancer 2001;91:319-323.
41. Perkins G, Middleton LP, Garcia SM: Male breast carcinoma: outcomes and predictors of local-regional failure in patients treated without radiation therapy. Breast Cancer Res Treat 2002;76:121.
42. Stranzl H, Mayer R, Quehenberger F, Prettenhofer U, Willfurth P, Stoger H, Hackl A: Adjuvant radiotherapy in male breast cancer. Radiother Oncol 1999;53:29-35.
43. Chakravarthy A, Kim CR: Post-mastectomy radiation in male breast cancer. Radiother Oncol 2002;65:99-103.
44. Schuchardt U, Seegenschmiedt MH, Kirschner MJ, Renner H, Sauer R: Role of percutaneous radiotherapy in male breast carcinoma. Strahlenther Onkol 1996;172:369-375.
45. Zabel A, Milker-Zabel S, Zuna I, Wannenmacher M, Debus J: External beam radiotherapy in the treatment of male breast carcinoma: patterns of failure in a single institute experience. Tumori 2005;91:151-155.
46. Giordano SH, Perkins GH, Broglio K, Garcia SG, Middleton LP, Buzdar AU, Hortobagyi GN: Adjuvant systemic therapy for male breast carcinoma. Cancer 2005;104:2359-2364.
47. Bagley CS, Wesley MN, Young RC, Lippman ME: Adjuvant chemotherapy in males with cancer of the breast. Am J Clin Oncol 1987;10:55-60.
48. Goss PE, Reid C, Pintilie M, Lim R, Miller N: Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955-1996. Cancer 1999;85:629-639.
49. Ribeiro G, Swindell R, Harris M, Banerjee S, Cramer A: A review of management of the male breast carcinoma based on an analysis of 420 treated cases. Breast 1996;5:141-146.
50. Donegan WL, Redlich PN, Lang PJ, Gall MT: Carcinoma of the breast in males: a multiinstitutional survey. Cancer 1998;83:498-509.
51. Pritchard KI, Messersmith H, Elavathil L, Trudeau M, O'Malley F, Dhesy-Thind B: HER-2 and topoisomerase II as predictors of response to chemotherapy. J Clin Oncol 2008;26:736-744.
52. Rudlowski C, Rath W, Becker AJ, Wiestler OD, Buttner R: Trastuzumab and breast cancer. N Engl J Med 2001;345:997-998.
53. Ribeiro G, Swindell R: Adjuvant tamoxifen for male breast cancer (MBC). Br J Cancer 1992;65:252-254.
54. Giordano SH, Hortobagyi GN: Leuprolide acetate plus aromatase inhibition for male breast cancer. J Clin Oncol 2006;24:e42-e43.
55. Nahleh ZA: Hormonal therapy for male breast cancer: a different approach for a different disease. Cancer Treat Rev 2006;32:101-105.
56. Harbeck N, Gerber B: Breast Cancer in Specific Situations. Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO), 2008. ago-online.de.